Retrophin Inc. (RTRX) had a rough trading day for Friday March 22 as shares tumbled 5.48%, or a loss of $-1.3 per share, to close at $22.43. After opening the day at $23.55, shares of Retrophin Inc. traded as high as $23.73 and as low as $22.42. Volume was 319,942 shares over 2,888 trades, against an average daily volume of n/a shares and a total float of 41.41 million.
As a result of the decline, Retrophin Inc. now has a market cap of $928.89 million. In the last year, shares of Retrophin Inc. have traded between a range of $33.00 and $19.77, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Retrophin Inc serves in the healthcare sector based in the United States. As a pharmaceutical products manufacturer, it develops drugs to treat serious and rare diseases. Its suite of drug candidates includes Chenodal, to combat gallstones; Cholbam, which is approved for the treatment of bile acid synthesis disorders and Thiola, which addresses kidney stone formation.
Retrophin Inc. is based out of San Diego, CA and has some 214 employees. Its CEO is Eric Dube.
Retrophin Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.